Following the widespread use of catheter-based solutions to treat aortic valve stenosis and mitral valve regurgitation, the tricuspid valve has become the focus of percutaneous techniques. However, despite the growing number of patients with severe tricuspid regurgitation (TR) who have been approached with transcatheter therapies, there are still some unmet clinical needs that limit its widespread use.